Effect of galanin on the growth hormone (GH) response to GH-releasing hormone in patients with Cushing's disease.

Giustina A, Bossoni S, Bussi AR, Pozzi A, Wehrenberg WB

Endocrine research1 Mar 1993Cited by 7 (Europe PMC)

PMID7681769DOI10.1080/07435809309035407PepBankPUB-07681769

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. 1 result from people.

01HumanRandomized controlled trialActivity measurement
In women with untreated Cushing's disease, the GH peak after intravenous GHRH(1-29)NH2 during saline infusion was blunted compared with normal controls.
In plain wordsIn women with Cushing's disease, growth hormone rose much less after GHRH(1-29)NH2 than in healthy women.
Peptide
Sermorelin
Outcome
DecreaseGH peak after GHRH in Cushing's disease versus controls (saline infusion)
Study
n = 9
Comparator
Normal adult women
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 micrograms · intravenousAs given in this study (human).
Measurements
Peak GH
1.2 micrograms/L
Cushing's disease
Peak GH
24.6 micrograms/L
normal controls
Source sentences
Summary
Patients with Cushing's disease showed blunted GH peaks after GHRH (1.2 +/- 0.4 micrograms/L) during saline infusion, as compared to normal controls (24.6 +/- 4.6 micrograms/L; p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
A bolus of human GHRH(1-29)NH2 (Geref, Serono, Italy), 100 micrograms in 1 mL saline, was injected IV at 0 minutes.
Summary · context
We studied 5 female subjects with untreated active Cushing's disease caused by micro-pituitary adenomas (age 43 +/- 6.7 years; BMI 30 +/- 0.7 kg/m2).
Summary · context
Four normal adult females, matched for age and body weight with the patients with Cushing's disease, were studied as controls.
Report a problemFND-0768176901

Studies that did not test the peptide alone3

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

02HumanNot a test of Sermorelin aloneRandomized controlled trialActivity measurement
In women with untreated Cushing's disease, GH levels after GHRH(1-29)NH2 were significantly lower than in controls, both with saline and with galanin.
In plain wordsIn women with Cushing's disease, growth hormone levels after GHRH(1-29)NH2 stayed lower than in healthy women, with or without galanin.
Peptide
Sermorelin
Outcome
DecreaseGH levels after saline and after galanin in Cushing's disease versus controls
Study
n = 9
Comparator
Normal adult women
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
GH levels were significantly lower both after saline and after galanin in patients with Cushing's disease as compared to normal controls.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 5 female subjects with untreated active Cushing's disease caused by micro-pituitary adenomas (age 43 +/- 6.7 years; BMI 30 +/- 0.7 kg/m2).
Summary · context
Four normal adult females, matched for age and body weight with the patients with Cushing's disease, were studied as controls.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0768176904
03HumanNot a test of Sermorelin aloneRandomized controlled trialActivity measurement
In women with untreated Cushing's disease, galanin infusion did not enhance the GH response to GHRH(1-29)NH2.
In plain wordsIn women with Cushing's disease, galanin did not increase the growth hormone response to GHRH(1-29)NH2.
Peptide
Sermorelin
Outcome
No significant changeGalanin effect on GH response to GHRH in Cushing's disease
Study
n = 5
Comparator
Saline infusion
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Peak GH
2.3 micrograms/L
galanin infusion, Cushing's disease
Source sentences
Summary
but not in patients with Cushing's disease (GH peak: 2.3 +/- 0.6 micrograms/L).
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 5 female subjects with untreated active Cushing's disease caused by micro-pituitary adenomas (age 43 +/- 6.7 years; BMI 30 +/- 0.7 kg/m2).
Summary · context
Four normal adult females, matched for age and body weight with the patients with Cushing's disease, were studied as controls.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0768176903
04HumanNot a test of Sermorelin aloneRandomized controlled trialActivity measurement
In normal women, galanin infusion significantly enhanced the GH response to GHRH(1-29)NH2 compared with saline infusion.
In plain wordsIn healthy women, galanin increased the growth hormone response to GHRH(1-29)NH2 compared with saline.
Peptide
Sermorelin
Outcome
IncreaseGalanin effect on GH response to GHRH in control women
Study
n = 4
Comparator
Saline infusion
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Peak GH
51.4 micrograms/L
galanin infusion, controls
Source sentences
Summary
During galanin infusion a significantly enhanced GH response to GHRH, as compared with saline infusion, was observed in control subjects (GH peak: 51.4 +/- 9.8 micrograms/L; p < 0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 5 female subjects with untreated active Cushing's disease caused by micro-pituitary adenomas (age 43 +/- 6.7 years; BMI 30 +/- 0.7 kg/m2).
Summary · context
Four normal adult females, matched for age and body weight with the patients with Cushing's disease, were studied as controls.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0768176902

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.